Increasing Survival of Patients with Severe SARS-CoV-2 Infection and/or Multi Organ Failure by up to 30% with ADVOS - ADVanced Organ Support

Projektinformationen

ADVOS-COVID-19

ID Finanzhilfevereinbarung: 961745

DOI

10.3030/961745

Projekt abgeschlossen

EK-Unterschriftsdatum 27 Juli 2020

Startdatum 1 Oktober 2020

Enddatum 30 Juni 2023

Finanziert unter

• INDUSTRIAL LEADERSHIP - Innovation In SMEs

Gesamtkosten

€ 1 381 605,00

EU-Beitrag

€ 951 946,10

Koordiniert durch

ADVITOS GMBH
Germany

Periodic Reporting for period 2 - ADVOS-COVID-19 (Increasing Survival of Patients with Severe SARS-CoV-2 Infection and/or Multi Organ Failure by up to 30% with ADVOS - ADVanced Organ Support)

Berichtszeitraum: 2021-10-01 bis 2023-06-30

Zusammenfassung vom Kontext und den Gesamtzielen des Projekts

ADVITOS` innovation – the ADVOS therapy system - has the potential to increase the survival of COVID-19 patients suffering from severe multi organ failure (MOF). First published clinical data show that ADVOS improves survival by up to 30% in critically ill patients on intensive care. The first COVID-19 patients with MOF have been treated with ADVOS in Germany with promising results. ADVITOS is a SME instrument Phase 2 beneficiary: ADVOS 880349 for device usability improvement, IoT integration, and market expansion. Following the urgent EU call for corona solutions, we applied for the blended finance option to speed up device production and installation in Germany and other EU countries. The applied funding and equity is necessary in therapy application, service and sales resources, as well as accelerated clinical evidence for medical indication guidance. Integrating fluid based blood oxygenation for comprehensive lung support and AI/digital capabilities will achieve additional therapy and outcome improvement. Each year, 60% of intensive care patients - 500,000 individuals in Western Europe and the US - die of MOF. The coronavirus outbreak will further increase this number dramatically as COVID-19 often leads to MOF. The innovative ADVOS therapy has the potential to revolutionize intensive care therapy of patients worldwide, as it is the first and only blood purification therapy combining liver, lung, kidney support and direct blood pH correction in 1 device (technology leader in removal of liver toxins and fast extracorporeal blood pH correction). It will help to save lives in the current epidemic. The ADVOS therapy is low-invasive as standard hemodialysis, so it can support by far more ICU patients than other devices (that have a higher risk profile).

Arbeit, die ab Beginn des Projekts bis zum Ende des durch den Bericht erfassten Berichtszeitraums geleistet wurde, und die wichtigsten bis dahin erzielten Ergebnisse

The first reporting period for this project oversaw considerable progress in the clarification of the development and testing specifications deemed indispensable for a successful device development. The feasibility of the various methods being researched to integrate oxygenation into the ADVOS device is currently being evaluated, based on which a technical roadmap shall be put into place in the form of developmental activities.

Fortschritte, die über den aktuellen Stand der Technik hinausgehen und voraussichtliche potenzielle Auswirkungen (einschließlich der bis dato erzielten sozioökonomischen Auswirkungen und weiter gefassten gesellschaftlichen Auswirkungen des Projekts)

It is intended that following the completion of this project, it shall be technologically and fiscally viable to integrate oxygenation into the ADVOS device. this will help us realize the immense potential to revolutionize intensive care therapy for patients worldwide. This relates especially to the removal of CO2 (also carried out by the ADVOS device), which relieves the lungs and reduces the need/invasiveness of ventilation.

Company Logo